Indeed, the Authors of the CYCLOPS study noted that since GLUT2 is only weakly rhythmic in HCC, a cancer often driven by MYC, the use of the GLUT2-targeting streptozocin should be timed to minimize dose-limiting toxicity in the liver and kidney [22]. This evidence concerns the gene SLC2A2 and cancer.